

- Adair FE, Bagg HJ. Experimental and clinical studies on the treatment of cancer by dichlorethylsulphide (mustard gas). *Ann Surg* 1931;93(1):190–199.
- Rhoads C. Nitrogen mustards in treatment of neoplastic disease. *JAMA* 1946;131:656–658.
- Coles B. Effects of modifying structure on electrophilic reactions with biological nucleophiles. *Drug Metab Rev* 1985;15:1307–1334.
- Pearson R, Songstad J. Application of the principle of hard and soft acids and bases to organic chemistry. *J Am Chem Soc* 1967;89:1827.
- Ross W. Alkylating agents. In: *Biological Alkylating Agents*. London: Butterworth; 1962.
- Elson LA. Hematological effects of the alkylating agents. *Ann N Y Acad Sci* 1958;68(3):826–833.
- Kushner BH, Kramer K, Modak S, et al. Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. *Bone Marrow Transplant* 2006;37(3):271–276.
- Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. *Oncologist* 2000;5(2):144–151.
- Tentori L, Graziani G. Recent approaches to improve the antitumor efficacy of temozolomide. *Curr Med Chem* 2009;16(2):245–257.
- Vistica DT. Cytotoxicity as an indicator for transport mechanism: evidence that murine bone marrow progenitor cells lack a high-affinity leucine carrier that transports melphalan in murine L1210 leukemia cells. *Blood* 1980;56(3):427–429.
- Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. *Genome Res* 2001;11(7):1156–1166.
- Sensenbrenner LL, Marini JJ, Colvin M. Comparative effects of cyclophosphamide, isophosphamide, 4-methylcyclophosphamide, and phosphoramide mustard on murine hematopoietic and immunocompetent cells. *J Natl Cancer Inst* 1979;62(4):975–981.
- Zhang F, Zhang L, Jing L, et al. (2013) High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia. *Exp Hematol* 2013;41:328–334.
- Montgomery JA, James R, McCaleb GS, et al. The modes of decomposition of 1,3-bis(2-chloroethyl)-1-nitrosourea and related compounds. *J Med Chem* 1967;10(4):668–674.
- Brundrett RB, Cowens JW, Colvin M. Chemistry of nitrosoureas: decomposition of Deuterated 1,3-bis(2-chloroethyl)-1-nitrosourea. *J Med Chem* 1976;19(7):958–961.
- Tew KD, Kyle G, Johnson A, et al. Carbamylation of glutathione reductase and changes in cellular and chromosome morphology in a rat cell line resistant to nitrogen mustards but collaterally sensitive to nitrosoureas. *Cancer Res* 1985;45(5):2326–2333.
- Anderson T, Schein PS, McMenamin MC, et al. Streptozotocin diabetes: correlation with extent of depression of pancreatic islet nicotinamide adenine dinucleotide. *J Clin Invest* 1974;54(3):672–677.
- Anderson T, McMenamin MC, Schein PS. Chlorozotocin, 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose, an antitumor agent with modified bone marrow toxicity. *Cancer Res* 1975;35(3):761–765.
- Schein PS, O'Connell MJ, Blom J, et al. Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). *Cancer* 1974;34(4):993–1000.
- Pieper RO. Understanding and manipulating O6-methylguanine-DNA methyltransferase expression. *Pharmacol Ther* 1997;74(3):285–297.
- Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? *Nat Rev Neurol* 2010;6(1):39–51.
- Tew K, Colvin OM, Jones RB. Clinical and high dose alkylating agents. In: Chabner BA, Longo DL, eds. *Cancer: Chemotherapy and Biotherapy: Principles and Practice*. Philadelphia: Lippincott-Raven; 2005: 283.
- Brookes P, Lawley PD. The reaction of mono- and di-functional alkylating agents with nucleic acids. *Biochem J* 1961;80(3):496–503.
- Penta JS, Poster DS, Bruno S, et al. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. *J Clin Pharmacol* 1981;21(8–9 Suppl):11S–22S.
- Colvin M, Hilton J. Pharmacology of cyclophosphamide and metabolites. *Cancer Treat Rep* 1981;65(Suppl 3):89–95.
- Elson L. Hematological effects of the alkylating agents. *Ann N Y Acad Sci* 1958;68:826–833.
- Cox PJ. Cyclophosphamide cystitis—identification of acrolein as the causative agent. *Biochem Pharmacol* 1979;28(13):2045–2049.
- Andriole GL, Sandlund JT, Miser JS, et al. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. *J Clin Oncol* 1987;5(5):799–803.
- Schacht RG, Feiner HD, Gallo GR, et al. Nephrotoxicity of nitrosoureas. *Cancer* 1981;48(6):1328–1334.
- Littler WA, Ogilvie C. Lung function in patients receiving busulphan. *Br Med J* 1970;4(5734):530–532.
- Mark GJ, Lehingar-Zadeh A, Ragsdale BD. Cyclophosphamide pneumonitis. *Thorax* 1978;33(1):89–93.
- Kreisman H, Wolkove N. Pulmonary toxicity of antineoplastic therapy. *Semin Oncol* 1992;19(5):508–520.
- Kumar R, Biggart JD, McEvoy J, et al. Cyclophosphamide and reproductive function. *Lancet* 1972;1(7762):1212–1214.
- Miller JJ 3rd, Williams GF, Leissring JC. Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. *Am J Med* 1971;50(4):530–535.
- Nicholson HO. Cytotoxic drugs in pregnancy: review of reported cases. *J Obstet Gynaecol Br Commonw* 1968;75(3):307–312.
- Reimer RR, Hoover R, Fraumeni JF Jr, et al. Acute leukemia after alkylating-agent therapy of ovarian cancer. *N Engl J Med* 1977;297(4):177–181.
- Penn I. Second malignant neoplasms associated with immunosuppressive medications. *Cancer* 1976;37(2 Suppl):1024–1032.
- Bhatia S, Constine LS. Late morbidity after successful treatment of children with cancer. *Cancer J* 2009;15(3):174–180.
- Calvert W. Alopecia and cytotoxic drugs. *Br Med J* 1966;2(5517):831.
- Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. *Ann Intern Med* 1981;94(1):66–72.
- Santos GW, Sensenbrenner LL, Burke PJ, et al. Marrow transplantation in man following cyclophosphamide. *Transplant Proc* 1971;3(1):400–404.
- de Jonge ME, Huitema AD, Beijnen JH, et al. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. *Br J Cancer* 2006;94(9):1226–1230.
- Baruchel S, Diezi M, Hargrave D, et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. *Eur J Cancer* 2006;42(14):2335–2342.
- Pratt CB, Goren MP, Meyer WH, et al. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. *J Clin Oncol* 1990;8(8):1399–1401.
- Eberly AL, Anderson GD, Bubalo JS, et al. Optimal prevention of seizures induced by high-dose busulfan. *Pharmacotherapy* 2008;28(12):1502–1510.
- Bonifazi F, Storci G, Bandini G, et al. Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation. *Haematologica* 2014;99(1):172–179.
- An N, Janech MG, Bland AM, et al. Proteomic analysis of murine bone marrow niche microenvironment identifies thioredoxin as a novel agent for radioprotection and for enhancing donor cell reconstitution. *Exp Hematol* 2013;41:944–956.
- Steinherz LJ, Steinherz PG, Manganicasa D, et al. Cardiac changes with cyclophosphamide. *Med Pediatr Oncol* 1981;9(5):417–422.
- Bastholt L, Johansson CJ, Pfeiffer P, et al. A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients. *Cancer Chemother Pharmacol* 1991;28(3):205–210.
- Tew KD, Glusker JP, Hartley-Asp B, et al. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. *Pharmacol Ther* 1992;56(3):323–339.
- Punzi JS, Duax WL, Strong P, et al. Molecular conformation of estramustine and two analogues. *Mol Pharmacol* 1992;41(3):569–576.
- Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. *J Clin Oncol* 1992;10(11):1754–1761.
- Tew K, Houghton JA, Houghton PJ. *Preclinical and Clinical Modulation of Anticancer Drugs*. Boca Raton, FL: CRC Press; 1993.
- Friedlos F, Davies L, Scanlon I, et al. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. *Cancer Res* 2002;62(6):1724–1729.
- Tew KD. TLK-286: a novel glutathione S-transferase-activated prodrug. *Expert Opin Investig Drugs* 2005;14(8):1047–1054.
- Borch RF, Valente RR. Synthesis, activation, and cytotoxicity of aldophosphamide analogues. *J Med Chem* 1991;34(10):3052–3058.
- Rosen LS, Laxa B, Boulos L, et al. Phase I study of TLK286 (Telcyta) administered weekly in advanced malignancies. *Clin Cancer Res* 2004;10(11):3689–3698.
- Sequist LV, Fidias PM, Temel JS, et al. Phase 1–2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. *J Thorac Oncol* 2009;4(11):1389–1396.
- Kavanagh JJ, Gershenson DM, Choi H, et al. Multi-institutional phase 2 study of TLK286 (TELICYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. *Int J Gynecol Cancer* 2005;15(4):593–600.
- Vergote I, Finkler N, del Campo J, et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. *Eur J Cancer* 2009;45(13):2324–2332.
- Chase M, Chung RY, Chioocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. *Nat Biotechnol* 1998;16(5):444–448.

62. Vey N, Giles F. Laromustine (cloretazine). *Expert Opin Pharmacother* 2010;11(4):657–667.
63. Pigneux A. Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy. *IDrugs* 2009;12(1):39–53.
64. Schiller GJ, O'Brien SM, Pigneux A, et al. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. *J Clin Oncol* 2010;28(5):815–821.
65. Eichbaum M, Bischofs E, Nehls K, et al. Bendamustine hydrochloride—a renaissance of alkylating strategies in anticancer medicine. *Drugs Today (Barc)* 2009;45(6):431–444.
66. Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours. *Br J Cancer* 2007;96(11):1692–1698.
67. Weide R, Hess G, Köppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas: a multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). *Leuk Lymphoma* 2007;48(7):1299–1306.
68. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. *J Clin Oncol* 2009;27(9):1492–1501.
69. van der Jagt R. Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes. *Expert Rev Hematol* 2013;6:525–537.
70. Ponisch W, Heyn S, Beck J, et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase I clinical trial OSHO - #077. *Br J Haematol* 2013;162:202–209.